PCRX Pacira Biosciences Inc.

Pacira BioSciences to Present at the 2021 Wedbush PacGrow Healthcare Virtual Conference

Pacira BioSciences to Present at the 2021 Wedbush PacGrow Healthcare Virtual Conference

PARSIPPANY, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 Wedbush PacGrow Healthcare Virtual Conference at 10:20 AM ET on Tuesday, August 10, 2021. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at . A replay of the webcast will also be available for two weeks following the event.

About Pacira         

Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit .





Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
EN
04/08/2021

Underlying

PCRXPacira Biosciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacira Biosciences Inc.

 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Health...

Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures -- Select findings demonstrate that the use of EXPAREL® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total healthcare costs over various follow-up periods — -- Reduced opioid use observed at 6 months post-surgery among Medicare Advantage patients with low back pain in THA Study -- BRISBANE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioScience...

April 13, 2026 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences to Participate in Fireside Chat at the 25th Annual ...

Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on Wednesday, April 15, 2026. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s ...

April 8, 2026 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Redu...

Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting -- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion -- BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced findings from two real-world studies evaluating the economic benefit...

March 30, 2026 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation

Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation -- Issues Statement in Response to DOMA’s Nomination of Director Candidates --  -- No Shareholder Action Required at This Time -- BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three director candidates to stand for election to the Pacira Board of Directors (the “Board”)...

March 11, 2026 1 EN
 PRESS RELEASE
Free
PCRX Pacira Bioscien...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), ...

March 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch